is synthesized ubiquitously and mediates many of the anabolic actions of GH. However, tissue mRNA levels suggest that the liver is a major source of IGF-I synthesis and, in large part, is responsible for circulating IGF-I; such endocrine IGF-I may have a role in the coordination of tissue anabolism and act in concert with tissue-derived growth factor (Daughaday & Rotwein, 1989) .
ANTIBODY DESIGN AND IMMUNIZATION STRATEGIES
Antibodies can be present in an animal via either passive or active immunization; both offer some benefits for regulated modulation of protein hormone function. Passive immunization is the administration of exogenous antibodies which have been derived from another animal, whereas active immunization is the generation of endogenous antibody by direct exposure of the host animal to small amounts of antigen. Active immunization, therefore, involves the injection of minute quantities of antigen (pg) which probably will not induce an independent physiological response and will be degraded rapidly. Antigen will only need to be administered as prime and boost immunizations in much the same manner as techniques used to confer disease resistance; this is likely, therefore, to be a more acceptable technological approach to the general public than that of hormone administration. Additionally, active immunization is likely to be long-lasting (months) compared with the short-term (days) effects of most protein hormones. In the case of passive immunization, exogenous antibodies will be cleared by the recipient animal and, therefore, will need to be administered regularly; antibody clearance will vary from a few hours to 3 weeks depending on whether or not antibodies are prepared from the same species. It is also likely that the recipient animal will raise antibodies against the administered antibodies if not self-species. The overall titre against the original antigen is important; obviously high titres are desirable and are more likely to be achieved via a successful active immunization than by passive immunization and subsequent dilution of antibody in vivo.
Protein function has been investigated using several different forms of antibodies. The most specific mechanistic data on hormone function can be generated using monoclonal antibodies (MAb) binding to a defined epitope; however, at present murine MAb are of little practical use for animal production purposes. Most commonly, immunization has been performed with intact hormone, leading to the production of polyclonal antibodies which have the potential to recognize many sites on the antigen, depending on its structure. Such antisera will usually be inhibitory because the 'peppering' of the surface of the hormone with high-affinity antibodies will prevent receptor interaction, even if no antibody directly interacts with the receptor binding region of the hormone. Antibody-mediated enhancement of hormone activity has been observed using both MAb and polyclonal antibody preparations. The interpretation of these observations depends on the several hypotheses currently under consideration to explain the phenomenon, and will be considered in more detail (see p. 624). However, if site-directed antibodies are required, it is possible to immunize with specific peptide regions of a protein, generating polyclonal antibodies but of restricted specificity to the intact protein; obviously these will only yield antibodies recognizing linear epitopes, whereas MAb usually bind to conformation epitopes consisting of discontinuous regions of the hormone.
INHIBITION OF SOMATOSTATIN ACTIVITY
In theory, immuno-neutralization of somatostatin should stimulate GH secretion from the pituitary gland, resulting in increased endogenous GH concentrations in blood. The initial studies, in growing lambs, demonstrated dramatic increases in weight gain (Spencer et al. 1985a,b) . Unfortunately, numerous subsequent studies have either refuted or supported these findings; no real consensus has emerged. Westbrook et al. (1993) have generated interesting data by immunizing pregnant ewes against somatostatin during the latter half of gestation and observing the subsequent performance of lambs during the immediate postpartum period. Milk yield at 2, 4 and 6 weeks post partum was significantly increased by 20-3096. Interestingly, the mean birth weight of lambs from immunized ewes was significantly greater than that for the control ewes and their growth rate was also increased significantly. The authors suggest that the anti-somatostatin-immunized animals were able to partition nutrients more efficiently towards the uterus and mammary gland. Subsequent studies have suggested that the presence of anti-somatostatin antibodies or an alternative bioactive factor in milk induced increased appetite and efficiency of nutrient utilization in lambs (Westbrook & McDowell, 1995) .
The reasons for the discrepant results of many anti-somatostatin studies are unclear, but might lie in consideration of the actions of somatostatin itself, which are wide-ranging and involve complex feedback mechanisms. A further possibility is experimental variation in achieving consistent high antibody titre and affinity for somatostatin. Current data suggest that, in quantitative terms, somatostatin function may be more focused towards gastrointestinal function than to its inhibition of GH secretion; a common feature of many anti-somatostatin studies is an increased efficiency of feed utilization (Elsaesser & Drath, 1995) .
ANTIBODIES AS HORMONE MIMICS
The potential of anti-idiotypes (secondary antibodies against primary antibodies) to act as protein mimics, and therefore function in a similar manner to the original antigen, has been explored in rodents using GH as the primary antigen. Anti-idiotypic antibodies were able to specifically inhibit GH binding to various tissues and, when given passively to hypophysectomized rats, were able to stimulate an increase in body-weight gain in an analogous fashion to GH (Gardner et al. 1990 ). The responsiveness of the rats to the antiidiotypic antibodies was much less than that to GH itself. One obvious explanation for this apparent insensitivity might be that only a particular set of anti-GH antibodies can act as an immunogen: those which recognize the receptor-binding site(s) of GH. These might not be generated with a sufficiently high titre and affinity. Since the crystal structure of GH binding to its receptor has been determined (de Vos et al. 1992), it might be possible to identify peptide regions of GH which are within the binding domain and could yield an immune response restricted to that part of the molecule. These antibodies could then be used to generate the anti-idiotypes; in practice, however, it is difficult to produce antipeptide antibodies with a high affinity for the molecule from which the peptide has been selected.
POTENTIATION OF HORMONE ACTIVITY
Holder et al. (1985) were the first to recognize the potential of increasing hormone activity for the improvement of growth efficiency. However, their initial observations were in hypopituitary rodents and, therefore, correction of a growth lesion was being investigated rather than the improvement of normal growth. Pel1 et al. (1989) provided evidence that this phenomenon could be extended to normal animals of production relevance. MAb raised against ovine GH (and which cross-react with bGH) enhanced the galactopoietic actions of exogenous bGH in lactating ewes. Of more interest, however, were observations on the diabetogenic action of GH in growing lambs (treatment with exogenous bGH inhibits insulin-induced decreases in blood glucose concentrations). Such a decrease in glucose concentration was almost completely abolished in lambs pre-treated with exogenous bGH which had been complexed to MAb OAl 1 . Interestingly, the insulininduced decrease in blood glucose concentrations was also significantly inhibited in lambs which had been administered MAb OAl 1 alone. Taken together these data imply that MAb cannot only potentiate the activity of exogenous hormone but also of endogenous hormone. The latter finding has clear significance for the improvement of growth efficiency; if animals could generate similar endogenous antibodies which could interact with endogenous hormone, then signalling via a particular hormone pathway could be enhanced. Of key importance in developing such an antibody response is the characterization of the properties of the original MAb which confer its enhancing activity so that suitable antigens could be designed. It is probable that these properties are either the site of binding to the antigen or the affinity of the antibody for the antigen.
At present, the mechanism of action of enhancing antibodies is unclear, although several have been proposed (see Pell & Aston, 1995) ; however, the enhancement of peptide hormone activity now appears to be a widespread phenomenon. In addition, even simple chemical cross-linking of GH, either to albumin or even to itself, apparently can potentiate GH activity . Thus, any proposed mechanism for hormone potentiation must be able to incorporate the diverse structure of the hormones potentiated, the varied nature of the antibodies used (MAb or polyclonal) and random NH2-mediated crosslinking; alternatively several mechanisms may exist. First, when the hormone-antibody complex is formed, an antibody-induced conformational change could occur in the hormone which increases the affinity of the hormone for its receptor. Such a phenomenon has been reported for GH when bound to a specific MAb (Mazza & Retegui, 1989) . Second, when a hormone can bind to several different receptor sub-types in vivo or to a binding protein, the presence of a site-directed antibody could restrict access of the hormone to one receptor and, therefore, increase availability to another receptor. Since some hormones, e.g. GRF, have only one known receptor, this 'restriction hypothesis' is probably not possible in all cases. A third hypothesis is simply that potentiating antibodies protect the hormone from degradation and decrease the clearance of bioactive hormone. Most peptide hormones are rapidly degraded in vivo, their half-lives being between 10 and 20min. The GH-enhancing anti-peptide antibodies reported by Aston et al. (1991) may protect a proteolytically-sensitive region of GH from degradation. Wang et al. (1992) have shown that accumulation of GH in tissues is greater in hypophysectomized rats treated with GH complexed to an enhancing antibody than when the hormone is given alone, suggesting that the antibody alters the pharmacokinetics and biodistribution of GH. Pharmacokinetic studies have demonstrated that insulin-enhancing antibodies act via a 'depot' or slowrelease mechanism, indicating a prolonged half-life (Gray et al. 1985) . Stewart et al. (1993) have shown that circulating IGF-I concentrations are significantly increased when IGF-I is pre-complexed to an enhancing antibody, implying that the peptide is protected from degradation. Indeed, the hypothesis that the bioavailability and, therefore, bioactivity of peptide and protein hormones may be modified by the formation of complexes in the pericellular environment is gaining increasing support, and specific antibodies may provide such a tier of regulation. A fourth suggestion is that some increase in receptor 'efficiency' occurs. Such a theory would help to account for the observations that enhancement can occur when antibody concentration is limited (Pell et al. 1989) . For example, a decrease in hormone-receptor internalization rate could occur when hormone is bound to antibody, so that contact between hormone and receptor is prolonged. Indeed, there is some evidence that enhancing MAb might increase total hormone occupancy of receptor without changing receptor number (Massart et al. 1993) .
Evidence can be found to support all the previously mentioned hypotheses, although some emerge as more likely than others. It is appropriate, therefore, to consider the more recent findings on antibody enhancement in relation to growth regulation.
Immuno-enhancement and inhibition of growth hormone-releasing factor activity in vivo and in vitro hGRF is a forty-or forty-four-residue peptide, which, unlike GH, is bioactive in many species. Full activity may be obtained with only residues 1-29 and this contains the receptor-binding domain of the peptide; the function of residues 30-44 is unknown but may be related to the stability of the peptide. We (Pel1 & James, 1995) examined the effects of site-directed anti-peptide antibodies raised against the N-and C-terminal regions of the peptide on the ability of GRF to stimulate GH release in vivo in sheep and in vitro using primary cultures of sheep pituitary cells. Fig. 1 shows circulating GH concentrations in sheep after a single dose of GRF, anti-1-14 or anti-35-44 immunoglobulin (Ig), or a preincubated mixture of Ig and GRF. GRF alone stimulated GH concentrations to a maximum of about 25 ng/ml within 30 min, followed by a decrease by 60 min; a biphasic response was observed in many animals with an additional smaller GH peak between 60 and 120min. Anti-1-14 Ig alone had no effect on GH concentrations, whereas the complex of anti-1-14 antibodies and GRF completely abolished the GRF-stimulated GH release. Anti-35-44 Ig pre-complexed to GRF induced a further stimulation of GH concentrations compared with GRF alone, partly due to an increase in the initial peak and also to an enhanced secondary peak. Interestingly, anti-35-44 Ig alone stimulated an increase in GH concentrations to almost the same extent as GRF alone, implying that the antibody could interact with endogenous GRF or had some effect on the GRF receptor. Concurrent studies in v i m have demonstrated that the anti-35-44 antibodies can enhance GRF in cultured pituitary cells, and also that the antibody does not interact directly with the GRF receptor (Pell & James, 1995) . These studies are compatible with three of the possible mechanisms for antibody enhancement of hormone activity listed previously. The key significance of this study is in the potentiation of hormone activity in vitro as well as in vivo, allowing consideration of changes in hormone-receptor interaction. The affinity and activity of GRF for its receptor can be increased by modification of its sequence to improve the amphiphilic properties of the peptide. For example, substitution of an alanine for glycine at residue 15 increases and extends the stability of the a-helical structure and creates a greater lipophilic face for membrane receptor binding (Kaiser & Kezdy, 1984; Clore et al. 1986; Campbell et al. 1991) . It is possible that antibodies directed against the C-terminal end of GRF might stabilize the a-helical structure of the NH2-terminal, thus increasing the affinity of the hormone for its receptor. In addition, the hormone-antibody complex could induce a decrease in receptor internalization rate compared with hormone alone, and this could in some manner lead to an increase in signalling. One hypothesis accounting for hormone enhancement in vivo is the protection of hormone degradation by antibodies. GRF is rapidly degraded in vivo, both by enzymic and chemical pathways, its half-life being between 10 and 20min ( Su et al. 1991; Boulanger et al. 1992) . Modification of GRF sequence to reduce degradation can induce increases in activity as GRF-stimulated GH release of threefold in vitro (rat pituitary cell culture) and elevenfold in vivo (Campbell et al. 1994) . Since the increase in activity was far greater in vivo, where hormone clearance is known to be important, these data demonstrate the scope for increasing the activity of certain peptide hormones in vivo merely by protection from proteolytic degradation. The function of the C-terminal fifteen residues of GRF is unknown, but it has been proposed that they increase the instability of the molecule since hGRF( 1-32)-OH is more stable than hGRF( 1-44)-NH2 (Campbell et al. 1994) ; it is possible, therefore, that antibody binding to the C-terminal may increase GRF stability.
Potentiation of growth hormone activity by active immunization with a synthetic peptide region of growth hormone
Possible regions of GH to which antibodies might bind were identified by prediction of peptide sequences likely to be on the surface of the molecule and with high mobility ; a panel of peptides were tested in hypopituitary mice for possible potentiation of GH activity and one was selected for further investigation in growing lambs (Pel1 & Aston, 1991). Subsequently multiple-pin peptide synthesis techniques (Geysen et al. 1984) were used. Lambs were immunized with a synthetic peptide derived from the loop region joining helices 3 and 4 and their subsequent carcass composition determined after 10 weeks exposure to auto-antibodies against the peptide in the presence and absence of exogenous GH. Final body composition is shown in Fig. 2 . Lambs treated with exogenous GH alone exhibited increased carcass protein and water content with simultaneous decreased fat content. However, Iambs exposed only to anti-peptide antibodies only had increased lean tissue mass without concomitant decreased fat content. Those lambs immunized against the peptide fragment of GH and administered GH did not have a further increase in lean tissue content compared with GH or peptide immunization alone but exhibited an intermediate fat content. These data, therefore, suggest that it is possible to auto-immunize animals and generate antibodies which might interact with endogenous hormones. Further, they also indicate that not all the properties of the original hormone are potentiated. This finding supports the 'restriction' hypothesis of antibody potentiation, i.e. that it is possible to direct hormone activity towards a particular receptor sub-type where receptor heterogeneity exists, although, with the observation that hormone potentiation can occur where only a single receptor exists, it is difficult to reconcile this as the only hypothesis.
Antibody enhancement of insulin-like growth factor-Z activity: analogy with naturally-occurring binding proteins
IGF-I is a multi-functional peptide which stimulates cellular proliferation and differentiation and is essential for normal growth and development (Liu et al. 1993; Powell-Braxton et al. 1993) . The potency of IGF-I is such that very little peptide is found in the free form in vivo; instead, it is bound to one of a family of at least six highly-specific IGF-binding proteins (IGFBP) which moderate IGF-I activity and are synthesized by individual tissues in a highly regulated manner (Rechler, 1994) . Even though the precise functions of each IGFBP are not characterized fully, IGFBP probably exert specific functions such as the targeting and transport of IGF-I to its receptors. Since IGF-I is secreted via the constitutive pathway, no conventional tissue stores exist and, therefore, a further important function of the IGFE3P is to maintain a reservoir of IGF-I. This can be attributed in particular to IGFBP-3 which binds in excess of 90 % of circulating IGF-I. IGFBP-3 may exist as either a binary complex with IGF-I or, after association with an additional protein (the acid-labile subunit; ALS), may form a ternary complex that is large enough to be confined to the circulation (Baxter & Martin, 1989) . Certain IGFBP (-1, -2, -3 and -5) modulate IGF-I activity by switching their normal inhibitory action to one of enhancement; precise mechanisms for such dual action are not fully elucidated but involve a reduction in the affinity of the IGFBP for IGF-I, closer to that of the IGF type 1 receptor (for comprehensive review, see Jones & Clemmons, 1995). Thus, a very sophisticated system appears to have evolved to maintain the circulating reservoir of IGF and control its delivery, availability and targeting to tissues. Antibodies have a similar molecular mass to that for the IGF-I-IGFBP-3-ALS ternary complex (150kDa) and, therefore, may provide a model for further elucidation of the function of the IGF ternary complex and its importance for IGF-I stability and bioavailability. We therefore investigated the actions of a specific anti-IGF-I antibody (raised in sheep against hIGF-I) and demonstrated that the antibody enhanced IGF-I activity in vivo . This is illustrated in Fig. 3 which shows the weight gain and circulating IGF-I concentrations for dwarf rats (low GH synthesis and secretion rate; Charlton et al. 1988) . Dwarf rats treated with an IGF-I-antibody complex exhibited increased weight gain and serum IGF-I concentrations compared with those treated with IGF-I alone. Interestingly, those administered anti-IGF-I Ig alone also tended to have increased weight gain and circulating IGF-I levels compared with rats given control Ig only, indicating that the Ig might interact with endogenous IGF-I. Since the antibody had a modest affinity for IGF-I, equivalent to that of the IGF type 1 receptor, we suggested that the antiserum might protect IGF-I from degradation whilst maintaining it in a bioavailable form. The aim of a further investigation (Hill et al. 1997) was to test that hypothesis by determining the plasma clearance and tissue distribution of tracer IGF-I in the presence of the enhancing anti-IGF-I Ig or non-immune Ig; the anti-IGF-I Ig did indeed reduce IGF-I metabolic clearance rate and degradation (Fig. 4(a and b) ). These data support the suggestion that enhancing antibodies can change the kinetics of peptide hormone metabolism in an analogous manner to one of the key putative functions of IGFBP.
CONCLUSIONS
The data presented in the present review suggest that it is possible to change peptide hormone activity using antibodies either as inhibitory or enhancing binding proteins; additionally, antibodies can be designed as structural and functional mimics of specific peptide motifs. These antibodies can either be produced in one animal and administered to another, or be induced in the animal of interest. The latter approach is probably better for the improvement of growth efficiency. However, such active immunizations will probably induce counter-regulatory mechanisms, which probably explains the variable responsiveness observed. It is, therefore, important that reaction to immunization with self-proteins (or peptides derived from self-proteins) is understood more clearly.
